Clinical trials: Triple Negative Breast Neoplasms, open to volunteers
Triple-negative Breast Cancer
Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
Breast cancer is one of the most common cancers among women. One in eight women in France will develop breast cancer during their lifetime (Inca).
- Trial name
- EPPIL (NCT07458204)
- Testing
- LVB infiltration
- Where
- France
- Volunteers
- 760 people
- Sponsor
- Institut Jean-Godinot
Breast Cancer
Arsenous Acid for Refractory Triple-Negative Breast Cancer
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of…
- Trial name
- NCT06678048
- Testing
- Arsenous Acid plus Chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Triple Negative Breast Cancer (TNBC)
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
CIRCADIAN is a prospective randomized clinical trial designed to evaluate the impact of pembrolizumab infusions' time-of-day on pathological complete response (pCR) rate among TNBC patients undergoing neoadjuvant treatment.
- Trial name
- CIRCADIAN (NCT06880029)
- Testing
- Morning pembrolizumab infusions
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT06434064
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Triple-negative Breast Cancer
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR)…
- Conditions
- Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
- Trial name
- NCT04138719
- Testing
- Nab-paclitaxel + Carboplatin, Nab-paclitaxel + Epirubicin
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Hebei Medical University Fourth Hospital
Triple Negative Breast Cancer
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
- Trial name
- NCT07332975
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pittsburgh
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with…
- Trial name
- PARTNER (NCT03150576)
- Testing
- Olaparib, Paclitaxel and Carboplatin
- Where
- 30 sites in United Kingdom
- Volunteers
- 780 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer
MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
The goal of this multi-centre, prospective study is to assess the frequency of asymptomatic brain metastasis in patients with stage IIb or III Triple Negative or HER2 positive breast cancer.
- Trial name
- NCT06247449
- Testing
- Brain imaging, Analysis of circulating tumor DNA, Testing Morbidities Index
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Triple-negative Breast Cancer (TNBC)
QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.
The study will evaluate the safety and efficacy of QLC5513 alone or in combination with QL1706 in patients with advanced or metastatic triple-negative breast cancer (TNBC) who had received ≥1 line of prior systematic therapy.
- Trial name
- NCT07509515
- Testing
- QLC5513, QLC5513+QL1706
- Volunteers
- 60 people
- Sponsor
- Fudan University
HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer.
- Conditions
- HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- Trial name
- NCT07730125
- Testing
- CRG-150
- Volunteers
- 67 people
- Sponsor
- CoRegen, Inc.
Triple Negative Breast Cancer, Non-Metastatic
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy
This clinical study aims to determine if skipping breast and axillary surgery could provide similar control of local and distant disease, with fewer complications and better quality of life, for triple-negative breast cancer…
- Trial name
- OMICHIR (NCT07357948)
- Testing
- Omission of surgery
- Where
- 4 sites in France
- Volunteers
- 150 people
- Sponsor
- Institut Curie
Triple Negative Breast Cancer Metastatic
Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)
This study is an open-label, prospective, phase 2, randomized controlled study to evaluate the efficacy and safety of apolitovorrelizumab (QL1706) in combination with platinum chemotherapy versus platinum chemotherapy in the…
- Trial name
- NCT07413601
- Testing
- QL1706, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TNBC - Triple-Negative Breast Cancer, TNBC
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation
This is an open-label, Simon's optimal two-stage design, single-arm, Phase II study with first 6 patients in the safety run-in portion.
- Trial name
- NCT07441512
- Testing
- Inavolisib in Combination With Eribulin
- Volunteers
- 26 people
- Sponsor
- Hu Hai
Triple Negative Breast Cancer
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
- Trial name
- NCT07283692
- Testing
- Serplulimab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- RenJi Hospital
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
Triple Negative Breast Cancer
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
- Trial name
- 4CAST (NCT04947189)
- Testing
- Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel
- Where
- Australia
- Volunteers
- 65 people
- Sponsor
- St Vincent's Hospital, Sydney
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
T-Cell Dysfunction, Chemotherapy Effect
Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer…
- Conditions
- T-Cell Dysfunction, Chemotherapy Effect, Adverse Events
- Trial name
- STFREiYTNBC (NCT06684054)
- Testing
- docetaxel, anthracycline, cyclophosphamide
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC)…
- Conditions
- HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer
- Trial name
- ENCORE (NCT06774027)
- Testing
- Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco